Search Result

Results for "

copd

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (3) Adenosine Receptor (14) Adrenergic Receptor (46) Akt (2) Antibiotic (2) Apoptosis (16) Autophagy (1) Bacterial (5) Biochemical Assay Reagents (1) Cadherin (1) Calcium Channel (1) Caspase (1) CCR (1) CFTR (2) Chloride Channel (2) CXCR (3) Cytochrome P450 (1) DNA/RNA Synthesis (2) Dopamine Receptor (2) Drug Isomer (2) Drug Metabolite (3) E1/E2/E3 Enzyme (1) Elastase (6) Endogenous Metabolite (5) Enterovirus (1) Epoxide Hydrolase (1) ERK (9) Formyl Peptide Receptor (FPR) (1) FOXO (1) G Protein-coupled Receptor Kinase (GRK) (1) Glucocorticoid Receptor (2) GPR109A (1) GSK-3 (1) HDAC (9) IKK (2) Integrin (2) Interleukin Related (17) Isotope-Labeled Compounds (10) JAK (1) Keap1-Nrf2 (5) Leukotriene Receptor (2) Lipase (1) mAChR (21) MDM-2/p53 (1) Mitochondrial Metabolism (1) MMP (2) Monoamine Oxidase (3) Mucin (1) Myosin (1) NF-κB (15) NOD-like Receptor (NLR) (2) Orthopoxvirus (2) Oxidative Phosphorylation (1) p38 MAPK (6) PERK (2) Phosphodiesterase (PDE) (40) PI3K (6) PROTACs (1) Reactive Oxygen Species (ROS) (3) Reference Standards (22) ROR (2) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (2) Src (1) STAT (1) TGF-beta/Smad (3) TGF-β Receptor (1) TNF Receptor (11) Topoisomerase (2) TRP Channel (1)
By Research Areas:	Cancer (31) Cardiovascular Disease (13) Endocrinology (13) Infection (13) Inflammation/Immunology (152) Metabolic Disease (7) Neurological Disease (23)
Oligonucleotides:	Human Pre-designed siRNA Sets (2) siRNAs (2)

186

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119708

Ensifentrine 1 Publications Verification RPL-554	Phosphodiesterase (PDE)	Infection Neurological Disease Inflammation/Immunology Cancer
Ensifentrine (RPL-554) is an inhaled dual inhibitor of PDE3 and PDE4 with IC₅₀s of 0.4 nM and 1479 nM, respectively. Ensifentrine blocks PDE3 and PDE4 enzymes, thereby increasing the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in lung cells, dilating the bronchi, and inhibiting the activation and migration of inflammatory cells. Ensifentrine can be used in the research of chronic obstructive pulmonary disease (COPD) .

HY-139206

LY3509754 4 Publications Verification IL-17A inhibitor 1	Interleukin Related	Inflammation/Immunology
LY3509754 (IL-17A inhibitor 1) is a IL-17A inhibitor, with IC₅₀ values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells .

HY-P99444

Astegolimab 2 Publications Verification MSTT 1041A; RG 6149	Interleukin Related MDM-2/p53 NF-κB	Cardiovascular Disease Inflammation/Immunology
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .

HY-14301

Olodaterol 1 Publications Verification BI1744	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Olodaterol (BI1744) is a selective, long acting β₂-adrenoceptor (β₂-AR) agonist (EC₅₀=0.1 nM and pK_i= 9.14 for human β₂-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .

HY-P99673

Itepekimab 1 Publications Verification REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

HY-D0205A

Carbocisteine Carbocysteine	NF-κB PERK Keap1-Nrf2 Apoptosis	Infection Inflammation/Immunology
Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research .

HY-14299

Indacaterol 5 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .

HY-P9923A

Benralizumab (anti-IL5RA ) 1 Publications Verification MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )	Interleukin Related Apoptosis	Inflammation/Immunology
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .

HY-B0944

Pidotimod 2 Publications Verification	Bacterial	Inflammation/Immunology
Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .

HY-153040

HPPE 3 Publications Verification Bach1-IN-1	Mitochondrial Metabolism	Metabolic Disease
HPPE (compound 236) is an orally active, potential Bach1 inhibitor. Bach1 is a transcription factor of the cap'n'collar type alkaline region leucine zipper factor family (CNC-bZip) that regulates mitochondrial metabolism and reduces glucose utilization. HPPE can be used for research in psoriasis, multiple sclerosis, and COPD .

HY-14144

Aclidinium Bromide 5 Publications Verification LAS 34273; LAS-W 330	mAChR	Inflammation/Immunology
Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research .

HY-19644

GSK2256294A 2 Publications Verification GSK 2256294	Epoxide Hydrolase	Cardiovascular Disease
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC₅₀s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease .

HY-14299A

Indacaterol maleate 5 Publications Verification QAB149	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .

HY-12463

Carmoterol hydrochloride	Adrenergic Receptor	Inflammation/Immunology
Carmoterol hydrochloride is a highly potent, selective and long-acting β2-adrenoceptor agonist with the pEC₅₀ of 10.19. Carmoterol has 53 times higher affinity for the β2-adrenoceptors than for the β1-adrenoceptors. Carmoterol hydrochloride can be used for the research of asthma and chronic obstructive pulmonary disease (COPD) .

HY-15545

AZD-4818	CCR	Inflammation/Immunology
AZD-4818 is a potent, orally active antagonist of chemokine CCR1. AZD-4818 can be used for researching chronic obstructive pulmonary disease (COPD) .

HY-B1675A

Levalbuterol hydrochloride (R)-Albuterol hydrochloride; (R)-Salbutamol hydrochloride; Levosalbutamol hydrochloride	Adrenergic Receptor	Inflammation/Immunology
Levalbuterol ((R)-Albuterol) hydrochloride is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol hydrochloride is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD .

HY-19519A

Ladarixin sodium 1 Publications Verification DF 2156A	CXCR	Infection Inflammation/Immunology Cancer
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma .

HY-19519

Ladarixin 1 Publications Verification DF 2156A free base	CXCR	Inflammation/Immunology Cancer
Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma .

HY-14301A

Olodaterol hydrochloride 1 Publications Verification BI1744 hydrochloride	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Olodaterol (BI1744) hydrochloride is a selective, long acting β₂-adrenoceptor (β₂-AR) agonist (EC₅₀=0.1 nM and pK_i= 9.14 for human β₂-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .

HY-10790

Cilomilast 3 Publications Verification SB-207499	Phosphodiesterase (PDE)	Inflammation/Immunology
Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC₅₀s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC₅₀=74, 65, >100, and 83 μM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) .

HY-109177

Icenticaftor QBW251	CFTR	Inflammation/Immunology
Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC₅₀s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research .

HY-136239

Beclomethasone 17-propionate 1 Publications Verification Beclomethasone-17-monopropionate; 17-BMP	Glucocorticoid Receptor Drug Metabolite	Inflammation/Immunology
Beclomethasone 17-propionate (Beclomethasone-17-monopropionate), an active metabolite of Beclomethasone dipropionate (HY-13571), is a glucocorticoid receptor (GR) agonist. Beclomethasone 17-propionate exhibits greater affinity for GR than Beclomethasone dipropionate. Beclomethasone 17-propionate effectively suppresses cytokine production in chronic obstructive pulmonary disease (COPD) lung macrophages .

HY-105092

Tetomilast OPC-6535	Phosphodiesterase (PDE)	Inflammation/Immunology
Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).

HY-111144

Abediterol AZD0548; LAS100977	Adrenergic Receptor	Inflammation/Immunology
Abediterol (LAS100977) is an inhaled long-acting β2-adrenoceptor agonist (LABA) and can be used for the research of asthma and chronic obstructive pulmonary disease (COPD) .

HY-B0010D

Arformoterol tartrate 1 Publications Verification (R,R)-Formoterol tartrate	Adrenergic Receptor	Inflammation/Immunology
Arformoterol ((R,R)-Formoterol) tartrate, the (R,R)-enantiomer of Formoterol, is a long-acting β2-adrenergic receptor (β2-AR) agonist, with a K_d of 2.9 nM. Arformoterol tartrate can be used for the research of chronic obstructive pulmonary disease (COPD) .

HY-14190

Valategrast R-411 free base	Integrin	Inflammation/Immunology
Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .

HY-108901

Formoterol hemifumarate hydrate 5+ Cited Publications	Adrenergic Receptor	Neurological Disease Inflammation/Immunology
Formoterol hemifumarate hydrate is a selective, long-acting beta 2-adrenoceptor agonist. Formoterol is a bronchodilator used for the research of the asthma and chronic obstructive pulmonary disease (COPD). Formoterol hemifumarate hydrate induces mitochondrial biogenesis and promotes cognitive recovery after traumatic brain injury .

HY-137976

Penehyclidine hydrochloride 1 Publications Verification Penequinine hydrochloride	mAChR NF-κB Apoptosis Autophagy Akt GSK-3 ERK	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Penehyclidine (Penequinine) hydrochloride, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine hydrochloride activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine hydrochloride can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .

HY-18862

PF-03715455	p38 MAPK	Inflammation/Immunology
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC₅₀ values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC₅₀=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .

HY-146346

HD-TAC7	PROTACs HDAC	Inflammation/Immunology
HD-TAC7 is a potent PROTAC HDAC degrader with IC₅₀ values of 3.6 μM, 4.2 μM and 1.1 μM for HDAC1, HDAC2 and HDAC3, respectively. HD-TAC7 can decreases NF-κB p65 in RAW 264.7 macrophages. HD-TAC7 can be used for the research of inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD) .

HY-B0010A

Arformoterol 1 Publications Verification (R,R)-Formoterol	Adrenergic Receptor	Inflammation/Immunology
Arformoterol ((R,R)-Formoterol), the (R,R)-enantiomer of Formoterol, is a long-acting β2-adrenergic receptor (β2-AR) agonist, with a K_d of 2.9 nM. Arformoterol can be used for the research of chronic obstructive pulmonary disease (COPD) .

HY-131910A

(R)-IHMT-PI3Kδ-372	PI3K	Inflammation/Immunology
(R)-IHMT-PI3Kδ-372 (R-18) is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 19 nM. (R)-IHMT-PI3Kδ-372 (R-18) can be used in chronic obstructive pulmonary disease (COPD) research .

HY-108047

MK-0873	Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .

HY-14301AR

Olodaterol hydrochloride (Standard) BI1744 hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Inflammation/Immunology Endocrinology
Olodaterol (hydrochloride) (Standard) is the analytical standard of Olodaterol (hydrochloride). This product is intended for research and analytical applications. Olodaterol (BI1744) hydrochloride is a selective, long acting β₂-adrenoceptor (β₂-AR) agonist (EC₅₀=0.1 nM and pK_i= 9.14 for human β₂-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .

HY-14299AR

Indacaterol maleate (Standard) QAB149 (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .

HY-120595

JNJ-49095397 RV568	p38 MAPK Src	Inflammation/Immunology
JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma .

HY-12463A

Carmoterol	Adrenergic Receptor	Inflammation/Immunology
Carmoterol is a highly potent and selective long-acting β2-adrenergic receptor agonist with a pEC₅₀ of 10.19. Carmoterol shows 53-fold higher affinity for β2-adrenergic receptors than for β1-adrenergic receptors. Carmoterol stimulates cyclic adenosine monophosphate accumulation, induces airway smooth muscle relaxation, inhibits bronchoconstriction, reduces thromboxane B₂ release, and prolongs survival time. Carmoterol can be used in research related to asthma and chronic obstructive pulmonary disease (COPD) .

HY-19830

AN3199	Phosphodiesterase (PDE)	Inflammation/Immunology
AN3199 is a PDE4 inhibitor with an IC₅₀ of 94.5 nM. AN3199 can be used for the research of inflammation-associated diseases such as asthma and chronic obstructive pulmonary disease (COPD) .

HY-14299R

Indacaterol (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .

HY-120802

Navafenterol AZD-8871; LAS191351	mAChR Adrenergic Receptor	Inflammation/Immunology
Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC₅₀ is 9.5 for human M3 receptor, and the pEC₅₀ is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .

HY-125251

D159153	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
D159153 is a highly selective phosphodiesterase 4 (PDE4) inhibitor. D159153 is promising for research of asthma, chronic obstructive pulmonary disease (COPD), and neuroinflammatory disorders .

HY-106293

ICI-200880	Elastase	Inflammation/Immunology
ICI-200880 is a potent, selective and reversible human neutrophil elastase (HNE) inhibitor. ICI-200880 is promising for research of inflammatory lung diseases related to neutrophil elastase, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) .

HY-B1675

Levalbuterol (R)-Albuterol; (R)-Salbutamol; Levosalbutamol	Adrenergic Receptor	Inflammation/Immunology
Levalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD .

HY-B1675AR

Levalbuterol hydrochloride (Standard) (R)-Albuterol hydrochloride (Standard); (R)-Salbutamol hydrochloride (Standard); Levosalbutamol hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Inflammation/Immunology
Levalbuterol (hydrochloride) (Standard) is the analytical standard of Levalbuterol (hydrochloride). This product is intended for research and analytical applications. Levalbuterol ((R)-Albuterol) hydrochloride is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol hydrochloride is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD .

HY-148525

PF-4348235 β2AR/M-receptor agonist-2	mAChR Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology
β2AR/M-receptor agonist-2 (compound 15) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-2 shows potency to β2 adrenoceptor with an EC₅₀ value of 3.7 nM. β2AR/M-receptor agonist-2 also has potency to human cloned M3 receptor with a K_i value of 0.73 nM. β2AR/M-receptor agonist-2 is a potent bronchodilator, it can be used for the research of chronic obstructive pulmonary disease (COPD) .

HY-145390A

(R,R)-Nrf2 activator-1	Keap1-Nrf2	Inflammation/Immunology
(R,R)-Nrf2 activator-1 is the enantiomer of Nrf2 activator-1. Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis .

HY-151198

CHF-6366	mAChR Adrenergic Receptor Calcium Channel	Inflammation/Immunology Endocrinology
CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pK_i values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC₅₀~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD) .

HY-178231

ALK5-IN-85	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-85 (Compound 19) is a TGFβRI (ALK5) inhibitor with an IC₅₀ < 100 ?nM. ALK5-IN-85 can be used for respiratory diseases including idiopathic pulmonary fibrosis, asthma, COPD and lumg cancer, and dermal and ocular fibrotic conditions research .

HY-131910

IHMT-PI3Kδ-372	PI3K Cytochrome P450	Inflammation/Immunology
IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research .

HY-143721

SSAO inhibitor-2	Monoamine Oxidase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .

Cat. No.	Product Name

HY-L932V0

Kinase Macrocyclic Compound Virtual Library

2,000,000 compounds

Macrocyclic compounds (≥12-atom cyclic small molecules/peptides) have unique physicochemical properties. They form preorganized conformations with high binding affinity/selectivity, target traditional small-molecule-inaccessible proteins, and bridge small-molecule drugs and biological agents. As key protein phosphorylation enzymes, kinases are linked to tumors, COPD, etc., and are critical therapeutic targets. Traditional small-molecule kinase inhibitors lack selectivity, causing off-target toxicity, low bioavailability, and acquired resistance. Macrocycles’ semi-rigid structure restricts conformations, boosts binding selectivity, optimizes pharmacokinetics, and makes macrocyclization a core kinase inhibitor optimization strategy.

Thousands of bioactive macrocycles were curated from ChEMBL. Via Transformer, macrocyclization was converted into a chemical language translation task, enabling end-to-end macrocycle generation from linear precursors with simplified inputs. Macformer achieves efficient, automated linear molecule macrocyclization via deep learning; generated macrocycles have diversity, novelty, biocompatibility, and cover broader chemical space.

MCE collected thousands of marketed/clinical kinase inhibitors, using their fragments for macrocyclization to generate derivatives. After evaluating synthetic accessibility and physicochemical properties, a million-scale virtual macrocyclic library was built for kinase-related virtual and AI-driven screening.

HY-L932V

Kinase Macrocyclic Compound Virtual Library

2,000,000 compounds

Cat. No.	Product Name	Target	Research Area

HY-P3293

Lonodelestat POL6014	Elastase	Inflammation/Immunology
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF) .

HY-P3293A

Lonodelestat TFA POL6014 TFA	Elastase	Inflammation/Immunology
Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF) .

HY-P10854

TAT-N15	NF-κB Interleukin Related STAT Akt	Neurological Disease Inflammation/Immunology
TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99444

Astegolimab 2 Publications Verification MSTT 1041A; RG 6149	Interleukin Related MDM-2/p53 NF-κB	Cardiovascular Disease Inflammation/Immunology
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .

HY-P99673

Itepekimab 1 Publications Verification REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

HY-P9923A

Benralizumab (anti-IL5RA ) 1 Publications Verification MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )	Interleukin Related Apoptosis	Inflammation/Immunology
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .

HY-P9923

Benralizumab 1 Publications Verification MEDI-563; BIW-8405; KHK4563	Interleukin Related Apoptosis	Inflammation/Immunology Cancer
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .

HY-P99872

Ecleralimab CSJ-117; NVP-CSJ117	Interleukin Related	Inflammation/Immunology
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .

HY-P991260

CNTO-6785	Interleukin Related	Infection
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0809

Theophylline Maximum Cited Publications 12 Publications Verification 1,3-Dimethylxanthine; Theo-24	Structural Classification Classification of Application Fields Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Alkaloids Immune System Disorder Other Alkaloids Disease markers Disease Research Fields Source Classification Theaceae Cancer	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-D0205A

Carbocisteine Carbocysteine	Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	NF-κB PERK Keap1-Nrf2 Apoptosis
Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research .

HY-N2807

Acanthoside B	Monophenols Cistanche salsa (C. A. Mey.) G. Beck Lignans Phenols Orobanchaceae Phenylpropanoids Plants Source Classification	Others
Acanthoside B is a potential bioactive lignan with anti-inflammatory and anti-amnesic activities. Acanthoside B can be used for alzheimer's disease and lung inflammation research

HY-B0809A

Theophylline monohydrate 5+ Cited Publications 1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809R

Theophylline (Standard) 5+ Cited Publications 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Alkaloids Immune System Disorder Classification of Application Fields Disease markers Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Disease Research Fields Source Classification Theaceae Cancer	Reference Standards Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-136409R

N-Decanoyl-L-homoserine lactone (Standard) C10-HSL (Standard)	Microorganisms Source Classification	Reference Standards Bacterial Reactive Oxygen Species (ROS)
Formoterol (hemifumarate hydrate) (Standard) is the analytical standard of Formoterol (hemifumarate hydrate). This product is intended for research and analytical applications. Formoterol hemifumarate hydrate is a selective, long-acting beta 2-adrenoceptor agonist. Formoterol is a bronchodilator used for the research of the asthma and chronic obstructive pulmonary disease (COPD). Formoterol hemifumarate hydrate induces mitochondrial biogenesis and promotes cognitive recovery after traumatic brain injury .

HY-D0205AR

Carbocisteine (Standard) Carbocysteine (Standard)	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Reference Standards Enterovirus
Carbocisteine (Standard) is the analytical standard of Carbocisteine. This product is intended for research and analytical applications. Carbocisteine, a mucolytic agent, can be used for the research of chronic obstructive pulmonary disease (COPD) .

HY-126232

Verproside	Plantaginaceae Infection Iridoids Veronica officinalis L. Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	NF-κB TNF Receptor IKK
Verproside, a catalpol derivative iridoid glycoside isolated from the genus Pseudolysimachion, represses TNF-α -induced MUC5AC expression by inhibiting NF-κB activation via the IKK/IκB signaling cascade. Verproside has potent anti-inflammatory, antioxidant, antinociceptive and anti-asthmatic activities. Verproside has the potential for the study of chronic obstructive pulmonary disease (COPD) .

HY-N8268R

Nordeoxycholic acid (Standard) 3α,12α-Dihydroxynorcholanic acid (Standard)	Animals Source Classification	Drug Metabolite Reference Standards
Reproterol (hydrochloride) (Standard) is the analytical standard of Reproterol (hydrochloride). This product is intended for research and analytical applications. Reproterol hydrochloride is a dual-acting beta2-adrenoceptor agonist and phosphodiesterase inhibitor. Reproterol hydrochloride is more potent than albuterol and feterol in stimulating cAMP production in human monocytes, demonstrating its potential in enhancing airway function. Furthermore, Reproterol significantly inhibited the production of LTB4, indicating its anti-inflammatory properties. Reproterol hydrochloride may have inhibitory effects in respiratory diseases such as asthma and COPD .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

Cat. No.	Product Name	Chemical Structure

HY-W744625

Olodaterol-d3 hydrochloride
Olodaterol-d₃ hydrochloride (BI1744-d₃ hydrochloride) is the deuterium labeled Olodaterol hydrochloride (HY-14301A). Olodaterol (BI1744) hydrochloride is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC₅₀=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .

HY-B0010AS

Formoterol-d3
Formoterol-d₃ is deuterium labeled Arformoterol. Arformoterol ((R,R)-Formoterol), the (R,R)-enantiomer of Formoterol, is a long-acting β2-adrenergic receptor (β2-AR) agonist, with a Kd of 2.9 nM. Arformoterol can be used for the research of chronic obstructive pulmonary disease (COPD) .

HY-176524S

PDE3/4-IN-3
PDE3/4-IN-3 (Compound 7) is an orally active dual PDE3/4 inhibitor with IC₅₀s of 0.17 and ≤50 nM for PDE3A and PDE4B2, respectively. PDE3/4-IN-3 significantly inhibits methacholine-induced bronchoconstriction in guinea pigs. PDE3/4-IN-3 can be used for chronic obstructive pulmonary disease (COPD) and asthma research .

HY-B0241S

Ipratropium-d3 bromide
Ipratropium-d₃ (bromide) is the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC₅₀ values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-119708S

Ensifentrine-d6
Ensifentrine-d₆ (RPL-554-d₆) is deuterium labeled Ensifentrine. Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 with IC₅₀s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research .

HY-B0241S1

Ipratropium-d7 bromide
Ipratropium-d₇ (bromide)eis the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC₅₀ values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-W707640

Salbutamol-d4
Salbutamol-d₄ (Albuterol-d₄; AH-3365-d₄) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .

HY-D0205AS1

Carbocisteine-13C3-1
Carbocisteine- ¹³C₃-1 (Carbocysteine- ¹³C₃-1) is ¹³C labeled Carbocisteine. Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research .

HY-B0809S1

Theophylline-d3

Theophylline-d₃ is deuterated labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-121246S

Fluorofenidone-d3

Fluorofenidone-d₃ (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .

HY-143683S

Theophylline-13C2,d6

Theophylline- ¹³C₂,d₆ (1,3-Dimethylxanthine- ¹³C₂,d₆) is the deuterium labeled and ¹³C-labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-D0205AS2

Carbocisteine-d3
Carbocisteine-d₃ (Carbocysteine-d₃) is deuterium labeled Carbocisteine. Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research .

Host:	Mouse (2)
Reactivity:	Human (2) Mouse (2) Rat (2) Dog (2)
Application:	IHC-P (2) ICC/IF (2) WB (2) FC (2)
Isotype:	IgG1 (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P88230

	ARCN1 Antibody (YA7914) copd	WB, IHC-P, ICC/IF, FC	Human, Dog, Rat, Mouse
	ARCN1 Antibody (YA7914) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ARCN1.

HY-P88230A

	ARCN1 Antibody (YA7914)(PBS only) copd	WB, IHC-P, ICC/IF, FC	Human, Dog, Rat, Mouse
	ARCN1 Antibody (YA7914) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ARCN1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks